Baltimore, MD (PRWEB) June 11, 2016 -- The complexity of clinical protocols in the early-phase clinical trial industry is continuing to increase at a rapid pace, including the need for enrollment of patients with acute and chronic diseases into Phase I and Phase II trials. In order to remain at the forefront of these trends, SNBL CPC is very pleased to expand its collaborative relationship, with University of Maryland, Baltimore(UMB), by working directly with the University of Maryland School of Medicine faculty physicians. This relationship will make patient recruitment services accessible to the biopharmaceutical industry within an even broader range of diseases.
The carefully developed plan for collaboration will allow for patient referrals across all disease states/departments, utilization of specialty equipment/testing at the University, and physician participation as a Primary Investigator or Sub Investigator, in their area of expertise. Patients enrolled will have access to all specialty and subspecialty services available at the University of Maryland Medical Center. Additionally, the University of Maryland School of Medicine faculty physicians will be integrally involved in the care that patients receive. The collaboration is a long standing effort between the President of the University Dr. Jay A. Perman, Dr. E. Albert Reece, the Dean of the School of Medicine, and Dr. Ryoichi Nagata, Chairman and CEO of SNBL Group, and Takeshi Yamakawa, CEO and President of SNBL CPC.
According to Dr. Ryoichi Nagata, Chairman and CEO of SNBL Group, “…since the inception of our company in 2005, SNBL CPC has continued to lead the way in high quality execution of increasingly complex early phase clinical trials. The expansion of the collaboration with the University of Maryland, Baltimore to include patient identification services is yet another example of our market-leading position.”
The University of Maryland, Baltimore is also very pleased with the expansion of the collaboration with SNBL CPC. Dr. Jay A. Perman, President of the University of Maryland Baltimore, said “SNBL CPC has been an important member of the Maryland biotech community and a strong collaborator with UMB since it moved into the University of Maryland BioPark in 2005. We are excited to be working even more closely with SNBL to assist the biopharmaceutical industry in developing more efficacious and safer medicines.”
Dr. E. Albert Reece, Dean of the University of Maryland School of Medicine, adds “The University of Maryland School of Medicine faculty physicians, who work at the University of Maryland Medical Center, practice discovery-based medicine, applying the latest advances in biomedical research to the care they deliver to patients. This partnership with SNBL CPC will give us the opportunity to offer innovative treatments to an even broader population.”
If you are interested in learning more about the collaboration between SNBL CPC and the University of Maryland, Baltimore, please address your questions to:
Christopher Hickey, MBA
Vice President of Business Development
SNBL Clinical Pharmacology Center, Inc.
800 W. Baltimore St., 5th Floor
Baltimore, MD 21201
Email: chickey(at)snbl-cpc.com
About SNBL CPC:
SNBL CPC is a 40,000 square foot, 96-bed clinical pharmacology research facility located in the University of Maryland BioPark in the heart of Baltimore, Maryland. Equipped with a state-of-the-art facility and bolstered by a vibrant research community, SNBL CPC specializes in complex Phase I-II trials, including TQT, FIH, and Challenge studies, in therapeutic areas including immunology/infectious disease, neurology, respiratory, dermatology, and more. SNBL CPC conducts clinical trials from multiple sectors, including pharmaceuticals, biotechnology, academia, and the government. SNBL CPC offers full service support of clinical trials through its in-house resources, expert partners from surrounding universities and practices, and vetted subcontractors. These services include medical writing, patient recruitment, clinical conduct, regulatory submission, and data management.
For further information about SNBL CPC and how it can support your early phase drug development, please contact Chris Hickey (chickey(at)snbl-cpc.com) or the client service team (bd(at)snbl-cpc.com), or visit http://www.snbl-cpc.com.
About University of Maryland, Baltimore:
UMB is Maryland's only public health, law, and human services university. Six professional schools and a Graduate School confer the majority of health care, human services, and law professional degrees in Maryland each year. Under the leadership of President Jay A. Perman, MD, the University is a leading partner in the redevelopment of Baltimore’s Westside. The University of Maryland BioPark, which opened in October 2005, promotes collaborative research opportunities and bioscience innovation. Sponsored research totaled $499.6 million in Fiscal Year 2015. With 6,329 students and 7,119 faculty members and staff, the University is an economic engine that returns more than $15 in economic activity for every $1 of state general funds appropriation. The University community gives more than 2 million hours a year in service to the public.
Christopher Hickey, SNBL Clinical Pharmacology Center, Inc., http://www.snbl-cpc.com, +1 4107068799, [email protected]
SOURCE SNBL Clinical Pharmacology Center, Inc.
Share this article